SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193805-23-001425
Filing Date
2023-10-18
Accepted
2023-10-18 16:05:55
Documents
13
Period of Report
2023-10-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 e619010_8k-immunic.htm   iXBRL 8-K 20252
2 e619010_ex10-1.htm EX-10.1 7440
  Complete submission text file 0001193805-23-001425.txt   203206

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE imux-20231017.xsd EX-101.SCH 2947
4 XBRL LABEL FILE imux-20231017_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE imux-20231017_pre.xml EX-101.PRE 22351
7 EXTRACTED XBRL INSTANCE DOCUMENT e619010_8k-immunic_htm.xml XML 3701
Mailing Address 1200 AVENUE OF THE AMERICAS SUITE 200 NEW YORK X1 10036
Business Address 1200 AVENUE OF THE AMERICAS SUITE 200 NEW YORK X1 10036 (332) 255-9818
IMMUNIC, INC. (Filer) CIK: 0001280776 (see all company filings)

IRS No.: 562358443 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36201 | Film No.: 231332289
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences